Festina lente: hydroxychloroquine, COVID-19 and the role of the rheumatologist
Open Access
- 1 June 2020
- journal article
- research article
- Published by BMJ in Annals Of The Rheumatic Diseases
- Vol. 79 (6), 734-736
- https://doi.org/10.1136/annrheumdis-2020-217480
Abstract
No abstract availableThis publication has 14 references indexed in Scilit:
- Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19)JAMA Cardiology, 2020
- Fair Allocation of Scarce Medical Resources in the Time of Covid-19The New England Journal of Medicine, 2020
- Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trialInternational Journal of Antimicrobial Agents, 2020
- Factors predictive of high disease activity early in the course of SLE in patients from a Latin-American cohortSeminars in Arthritis and Rheumatism, 2017
- Metabolic and cardiovascular benefits of hydroxychloroquine in patients with rheumatoid arthritis: a systematic review and meta-analysisAnnals Of The Rheumatic Diseases, 2017
- The global burden of SLE: prevalence, health disparities and socioeconomic impactNature Reviews Rheumatology, 2016
- Microevolution of Outbreak-Associated Middle East Respiratory Syndrome Coronavirus, South Korea, 2015Emerging Infectious Diseases, 2016
- Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception CohortAnnals Of The Rheumatic Diseases, 2014
- Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L)Annals Of The Rheumatic Diseases, 2007
- A Randomized Study of the Effect of Withdrawing Hydroxychloroquine Sulfate in Systemic Lupus ErythematosusThe New England Journal of Medicine, 1991